SPL-707

• UNSPSC Description:

  SPL-707 is an orally active, selective signal peptide peptidase-like 2a (SPPL2a) inhibitor with an IC50 of 77 nM for hSPPL2a. SPL-707 inhibits γ-secretase (IC50=6.1 μM) and SPP (IC50=3.7 μM). SPL-707 has the potential for autoimmune diseases research by targeting B cells and dendritic cells[1].

• Target Antigen:

  γ-secretase

• Type:

  Reference compound

• Related Pathways:

  Neuronal Signaling;Stem Cell/Wnt

• Applications:

  COVID-19-immunoregulation

• Field of Research:

  Inflammation/Immunology

• Assay Protocol:

  https://www.medchemexpress.com/SPL-707.html

• Purity:

  99.94

• Solubility:

  DMSO : 100 mg/mL (ultrasonic)

• Smiles:

  CC1=C(NC(C[C@@H](C2CC2)C(N[C@@H]3C(N(CC4(CC4)C5)N5C(C6=C3C=CC=C6)=O)=O)=O)=O)C=C(F)C=N1

• Molecular Weight:

  505.54

• References & Citations:

  [1]Velcicky J, et al. Discovery of the First Potent, Selective, and Orally Bioavailable Signal Peptide Peptidase-Like 2a (SPPL2a) Inhibitor Displaying Pronounced Immunomodulatory Effects In Vivo. J Med Chem. 2018 Feb 8;61(3):865-880.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Clinical Information:

  No Development Reported

• CAS Number:

  2195361-33-0